Generalized Anxiety Disorder Therapy, Associated with Pronounced Side Effects, and Prospects for the Use of Pharmacogenetic Testing: Case report
https://doi.org/10.52667/2712-9179-2023-3-1-59-65
Abstract
New generation antidepressants (AD) are widely used as first-line treatment for generalized anxiety disorder (GAD) and considered safely than tricyclics. Some side effects of AD are transient and may disappear after few weeks of treatment, but potentially severe may persist for a long time or occur later. Cardiovascular disorders (abnormal heart rhythm, QT prolongation, arterial hypertension, orthostatic hypotension) are especially dangerous side effects. Genetic polymorphisms of the enzymes involved in the metabolism of antidepressants may be one of the causes of side effects development. The objective of this case report is to demonstrate that timely assessment of the risk of side effects using pharmacogenetic testing (PGx) could have influenced choice of an antidepressant, timely dose adjustment, avoiding ineffective appointments. Use of the PGx can help to optimize GAD pharmacotherapy, its introduction into clinical practice requires further research.
About the Authors
A. I. Strelnik
International Centre for Education and Research in Neuropsychiatry, Samara State Medical University; Department of Psychiatry, Narcology and Psychotherapy, Samara State Medical University
Russian Federation
Russian Federation
Anna I. Strelnik
443016 Samara
Tel.: +79371770324
D. V. Romanov
Department of Psychiatry, Narcology and Psychotherapy, Samara State Medical University
Russian Federation
Russian Federation
Dmitriy V. Romanov
443016 Samara
S. N. Strelnik
Department of Psychiatry, Narcology and Psychotherapy, Samara State Medical University
Russian Federation
Russian Federation
Sergey N. Strelnik
443016 Samara
References
1. Terlizzi, E.P.; Villarroel, M.A. Symptoms of Generalized Anxiety Disorder Among Adults: United States, 2019. NCHS Data Brief. 2020, 378, 1-8.
2. DeMartini, J.; Patel, G.; Fancher, T.L. Generalized Anxiety Disorder. Ann Intern Med. 2019, 170(7), ITC49-ITC64. doi:10.7326/AITC201904020
3. Cipriani, A.; Furukawa, T. A.; Salanti, G.; Geddes, J. R.; Higgins, J. P.; Churchill, R.; Watanabe, N.; Nakagawa, A.; Omori, I. M.; McGuire, H.; Tansella, M.; Barbui, C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multipletreatments meta-analysis. Lancet 2009, 373(9665), 746–758. https://doi.org/10.1016/S0140-6736(09)60046-5
4. Taylor, C.B. Depression, heart rate related variables and cardiovascular disease. Int J Psychophysiol. 2010, 78(1), 80-88. doi:10.1016/j.ijpsycho.2010.04.006
5. Dobrodeeva, V.S.; Shnayder, N.A.; Nasyrova, R.F. Pharmacogenetic aspects of the efficacy and safety of trazodone therapy. Farmakogenetika i farmakogenomika 2019, 1, 25–28. (In Russ). DOI: 10.24411/2588-0527-2019-10038
6. Herbild, L.; Andersen, S.E.; Werge, T.; Rasmussen, H.B.; Jürgens, G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharmacol Toxicol. 2013, 113(4), 266-272. doi:10.1111/bcpt.12093
Review
For citations:
Strelnik A.I., Romanov D.V., Strelnik S.N. Generalized Anxiety Disorder Therapy, Associated with Pronounced Side Effects, and Prospects for the Use of Pharmacogenetic Testing: Case report. Personalized Psychiatry and Neurology. 2023;3(1):59-65. https://doi.org/10.52667/2712-9179-2023-3-1-59-65
Views:
618
Email this article 